BOSTON, Mass. and TOKYO, Japan, July 28, 2026
CORE Biomedicine has entered into an exclusive global licensing agreement with Eisai Co., Ltd., securing worldwide rights to develop and commercialize multiple preclinical precision oncology programs designed to address significant unmet medical needs across a broad range of cancers. The agreement provides CORE Biomedicine with access to innovative oncology assets originally discovered through research conducted by Eisai and its affiliates, strengthening the company’s mission to build a next-generation precision medicine portfolio based on lineage biology and advanced cancer research. The strategic licensing deal significantly expands CORE’s pipeline of novel oncology candidates while reinforcing its long-term vision of translating cutting-edge cancer biology into transformative therapies for patients worldwide. By combining Eisai’s scientific discoveries with CORE’s expertise in oncology drug development, the collaboration is expected to accelerate the advancement of innovative cancer therapies from preclinical research toward future clinical development, positioning the company as an emerging leader in precision oncology innovation.
Exclusive Licensing Agreement Strengthens Oncology Portfolio
The licensing agreement grants CORE Biomedicine exclusive global rights to a portfolio of preclinical oncology programs targeting key molecular drivers involved in multiple forms of cancer. These investigational assets represent years of research conducted by Eisai, one of the world’s leading oncology-focused pharmaceutical companies, and include multiple therapeutic programs directed at distinct molecular targets and biological pathways. The newly licensed portfolio provides CORE with a strong scientific foundation to expand its precision oncology pipeline while supporting the discovery of first-in-class and best-in-class cancer therapies. Rather than focusing solely on genomic mutations, CORE’s development strategy utilizes lineage-based precision medicine, an innovative approach that examines the biological identity of cancer cells to identify broader therapeutic opportunities. According to Dr. Douglas McMillin, Co-Founder and Head of Business Development at CORE Biomedicine, the licensed programs possess significant potential to address unmet medical needs across numerous cancer indications while supporting the company’s commitment to efficiently advancing novel therapies toward clinical evaluation.
Lineage Biology Drives Next-Generation Cancer Drug Development
CORE Biomedicine is building its research strategy around lineage biology, an emerging precision medicine approach that goes beyond traditional genomic profiling by targeting the fundamental biological mechanisms responsible for cancer cell identity and behavior. This strategy enables researchers to identify therapeutic opportunities shared across multiple tumor types, potentially expanding patient populations that may benefit from targeted therapies. Through the newly acquired oncology programs, CORE plans to leverage its extensive expertise in cancer biology, drug discovery, and translational research to accelerate the progression of promising candidates into clinical development. The agreement also demonstrates increasing industry recognition of lineage-based therapeutics as a complementary strategy to conventional precision oncology, offering the potential to improve treatment outcomes while addressing cancers that remain difficult to treat using existing targeted therapies. By integrating scientific innovation with focused drug development capabilities, CORE aims to establish a differentiated pipeline capable of delivering meaningful advances for patients with complex malignancies.
Advertisement
Strategic Collaboration Advances Global Precision Medicine Innovation
The partnership further strengthens CORE Biomedicine’s international presence across the United States, Japan, and China, providing a robust platform for global oncology research and future clinical development. Eisai, recognized for its long-standing commitment to developing innovative therapies in oncology and neurology, continues to support scientific innovation by enabling specialized biotechnology companies to advance promising research programs through dedicated development strategies. The agreement allows CORE to focus resources on advancing these preclinical assets toward future clinical milestones while expanding collaborations across the global biotechnology ecosystem. As demand continues to grow for precision oncology therapies capable of addressing diverse patient populations, this licensing agreement positions CORE Biomedicine to play an increasingly important role in the future of targeted cancer treatment. By combining innovative science, strategic licensing, and deep oncology expertise, the company is strengthening its ability to develop transformative precision medicines designed to improve outcomes for cancer patients worldwide and accelerate the next generation of oncology drug innovation.
Source: CORE Biomedicine, Eisai press release
